Company logo
Sector: Healthcare
Industry: Biotechnology

Ultragenyx Pharmaceutical Inc

Ticker - RARE
Country: US
Exchange: NASDAQ

Monitor Performance using this Dynamic, Always Current, Periodic Table of Investments

Data:

Time:

Alignment:

About Ultragenyx Pharmaceutical Inc

  • Company Overview: U.S.-listed RARE, associated with the ticker "RARE," refers to Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases. Founded in 2010, Ultragenyx is headquartered in Novato, California.
  • Business Model: Ultragenyx operates under a biopharma business model centered on researching and developing therapeutics for rare genetic disorders. Their strategy includes a strong emphasis on proprietary drug development, collaboration with patient advocacy groups, and a portfolio approach that balances risk across multiple product candidates.
  • Core Products and Pipeline: The company has several approved products and a diverse pipeline targeting various rare diseases.
    • Approved Products:
      • Crysvita (burosumab-twza): Approved for treating X-linked hypophosphatemia (XLH), a rare genetic disorder causing phosphorus deficiency.
      • Mepsevii (velmanase alfa): Enzyme replacement therapy for Mucopolysaccharidosis VII (MPS VII).
      • Dojolvi (triheptanoin): A dietary supplement approved for the treatment of long-chain fatty acid oxidation disorders.
    • Pipeline: The pipeline includes investigational drugs targeting conditions such as Angelman syndrome and other rare metabolic disorders, highlighting the company’s ongoing commitment to addressing unmet medical needs.
  • Approved Products:
    • Crysvita (burosumab-twza): Approved for treating X-linked hypophosphatemia (XLH), a rare genetic disorder causing phosphorus deficiency.
    • Mepsevii (velmanase alfa): Enzyme replacement therapy for Mucopolysaccharidosis VII (MPS VII).
    • Dojolvi (triheptanoin): A dietary supplement approved for the treatment of long-chain fatty acid oxidation disorders.
  • Crysvita (burosumab-twza): Approved for treating X-linked hypophosphatemia (XLH), a rare genetic disorder causing phosphorus deficiency.
  • Mepsevii (velmanase alfa): Enzyme replacement therapy for Mucopolysaccharidosis VII (MPS VII).
  • Dojolvi (triheptanoin): A dietary supplement approved for the treatment of long-chain fatty acid oxidation disorders.
  • Pipeline: The pipeline includes investigational drugs targeting conditions such as Angelman syndrome and other rare metabolic disorders, highlighting the company’s ongoing commitment to addressing unmet medical needs.
  • Operations: Ultragenyx engages in preclinical and clinical drug development, typically utilizing an accelerated timeline for product development owing to the urgency in addressing rare diseases. The company also emphasizes maintaining scientific rigor in its trials and utilizes platforms for gene therapy and other innovative approaches.
  • Financial Position: Ultragenyx is primarily funded through a combination of revenues from approved products and capital raised in public offerings. Investors should be aware of the potential for volatility in revenue streams as the company continues to invest heavily in R&D, often resulting in operating losses typical for pharmaceutical companies in this stage of development.
  • Market Position and Competitive Dynamics: The rare disease market is characterized by high barriers to entry, including regulatory hurdles and extensive research requirements. Ultragenyx competes with other biopharmaceutical companies and gene therapy firms focused on similar therapeutic areas. Their established products provide a foothold in the market, allowing for constant evaluation of competition and strategic pricing dynamics for their therapies.
  • Risks and Challenges: Investors should consider the risks inherent in drug development, including clinical trial failures, regulatory setbacks, and the high cost of bringing a drug to market. Given the niche market of rare diseases, the company may face market access challenges despite having innovative therapies. Furthermore, dependency on a limited product line could expose the company to revenue fluctuations, particularly as pipelines mature or face delays.
    • SWOT ANALYSIS

    SWOT Analysis is a strategic planning tool used to identify and understand the key factors that can impact a business or project. What are the key factors for gaining a competitive market share advantage? Also, what potential threats should we be wary of during our Process?

    STRENGTHS

    • Specializes in treatments for rare diseases, positioning itself in a niche market with high unmet medical needs.
    • Strong pipeline of innovative therapies supported by robust research and development capabilities.
    • Established partnerships with healthcare providers and organizations enhance market reach and credibility.

    WEAKNESSES

    • Heavy reliance on a limited number of products for revenue generation, increasing vulnerability to market fluctuations.
    • High operational costs associated with drug development can strain financial resources.
    • Regulatory hurdles may delay product launches and impact revenue timelines.

    OPPORTUNITIES

    • Expansion into new therapeutic areas could diversify revenue sources and reduce risk exposure.
    • Growing awareness and diagnosis of rare diseases may increase demand for specialized treatments.
    • Potential for strategic collaborations and acquisitions to strengthen product offerings and market presence.

    THREATS

    • Intense competition from other biopharmaceutical companies may pressure pricing and market share.
    • Changes in healthcare regulations and reimbursement policies could adversely affect profitability.
    • Market volatility and economic downturns may impact investment and consumer spending in healthcare sectors.

    Please enjoy this free portfolio visualization and monitoring tool. Click Install from the address bar for easy and fast future access.

    Paid accounts can visualize any portfolio or watchlist in this performance visualization… plus a million other cool things — including daily data, sharing custom tables for the assets you care about, industry-leading portfolio backtesting, and full portfolio strategy analytics. Both individual and professional versions are supported.

    Performance Disclosure

    This portfolio is hypothetical.


    This is a historical simulation of the portfolio performance an investor would have obtained had you invested in the same selections at the beginning of the simulation. This report provides information on how the portfolio holdings would have changed and would have performed for a certain period. We have strived to reduce or eliminate potential biases in the process to provide the most accurate assessment of the performance prospects of the strategy. However, it may not be possible for any historical simulation to completely ensure it is free of all biases.


    Please see
    Gold Standard for Portfolio Backtesting and
    Seven Deadly Sins of Portfolio Backtesting
    for a more complete understanding of risks and biases when backtesting portfolio strategies.


    Backtested strategies also run the risk of cherry picking. Cherry Picking is when the author of the backtest has created many variations and is presenting one of the variations that is more favorable. This research was not produced in whole or in part by cherry picking.


    This simulation is based on an account with tax exempt or tax deferred growth. Taxable accounts will have to pay the appropriate taxes for dividends, interest, and capital gains, which will decrease the performance depicted.


    This simulation is not based on actual trading accounts or account composites which may or may not exist for this strategy and may be materially different including worse than the performance illustrated above. Past performance is not necessarily indicative of future performance. Performance results including risk and diversification measures are not guaranteed to persist in the future.


    This historical performance simulation has been adjusted to reflect estimated management fees.


    The suitability of this portfolio strategy requires that you have thoughtfully and accurately completed your investor objectives from your accounts’ Investment Policy Statement. Login


    Diversification strategies alone cannot assure a successful investment outcome. Strategies offering greater diversification also fail to guarantee any reduction in loss of capital.


    Your ability to follow this investment strategy is a risk. Investors often dispose of successful strategies at inopportune times thus turning potentially profitable strategies into losses.


    Portfolio data is taken from sources believed to be accurate, however, there is no warranty or guarantee as to the accuracy or completeness of data and statistical calculations thereupon. Portfolio ThinkTank does not furnish investment advice without an investment advisory agreement.


    The period of time selected for analysis may have a significant bearing on the relative attractiveness of the strategy and the strategy versus another portfolio or benchmark. The author of the strategy controls the default period of time used to analyze performance and from there, users may select any desired period of time from the menu. In general, longer periods, greater diversification and lower concentrations of holdings result in more credible, more persistent performance evaluations.


    If this strategy includes predictions created by our deep learning neural net, there are additional risks that portfolio strategies and their backtested performance may have risks of having the data be overfit and consequently perform better in the backtest than it may in real account performance. We manage these risks regularly and in many ways. However, due to the attention mechanisms in a deep learning neural network, it may not be possible to eliminate these risks. To learn if your portfolio strategy is built using predictions from a neural network or to better understand our mitigation policies, we invite you to start a conversation: hello@gravityinvestments.com